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ing of malignant lymphoma, and can FSE STIR whole body MRI replace conventional staging pro-
cedures including computed tomography and bone marrow biopsy in initial staging of lymphoma.
Materials and methods: Twenty one newly diagnosed histologically proven lymphoma patients
underwent whole body MR imaging and conventional staging procedures including computed
tomography and bone marrow biopsy for initial staging of lymphoma using Modiﬁed Ann Arbor
staging system. Both methods evaluated positive involvement by lymphoma to the nodal and
extra-nodal sites including parenchymal organs, serosal cavities and bone marrow. The numbers
of involved nodal and extra-nodal sites detected by both methods were compared, then agreement
and disagreement between whole-body MRI and conventional procedures regarding lesions detec-
tion and staging according to the Ann Arbor staging system were calculated, along with binomial
exact 95% conﬁdence intervals (CIs).
Results: Twenty one patients had a total of 145 abnormalities. One hundred and twenty four were
correctly diagnosed by conventional staging procedures, however, FSE STIR whole body MRI cor-
rectly diagnosed all the 144 abnormalities with 1 false negative and 3 false positive abnormalities with
a total of detected abnormalities of 147 lesions. FSE STIR whole body MRI was signiﬁcantly more
accurate than conventional staging procedures in the diagnosis of positive lymphoma lesions
[(99.3%; 95% CI: 95.6–100.0%) versus (85.5%; 95% CI: 78.5–90.6%)]. FSE STIR whole body
MRI correctly staged 20 out of 21 patients, Kappa test 0.93 (P< 0.001) while conventional staging
procedures correctly staged 17 and incorrectly staged 4 cases, Kappa test 0.74 (P< 0.001).4038955.
m (G.K. Gouhar).
of Radiology and Nuclear
tian Society of Radiology and
lsevier
evier B.V.Open access under 
78 M.A. El-Hariri et al.Conclusion: Whole body MR imaging can replace conventional staging procedures in the diagnosis
and initial staging of malignant lymphoma as it offers a whole body overview of the lymphoma inﬁl-
tration through the lymph node stations, parenchymal organs, serosal cavities and bone marrow.
 2011 Egyptian Society of Radiology and Nuclear Medicine. Production and hosting by Elsevier B.V.
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Cancer is the second cause of death among children after acci-
dents [1]. Lymphoma is the third childhood malignancy and
accounts for 10% of child cancers, two thirds are NHL and
one third is HD [2].
In hematological malignancies the patients’ prognosis and
therapeutic options depend strongly on initial accurate diagno-
sis as well as tumor staging [3]. Clinical staging usually entails
different radiological examinations so it can be time consum-
ing and costly [4].
CT has historically been considered the standard imaging
technique for staging, however, benign nodal enlargement is
common among pediatric population [5,6]. Although MRI
examination is a safer alternative technique, it has been limited
by long examination time [7]. The advances in imaging tech-
nology and the introduction of moving patient platforms with
integrated surface coil technology have greatly reduced the
imaging time, especially for whole-body MR imaging [8–12].
Whole-body MRI has been widely adopted as a valuable
imaging tool in oncology and particularly in assessing diseases
that inﬁltrate through the body such as carcinoma and lym-
phoma [13]. A high-spatial-resolution whole body MRI exam-
ination with a reasonable time has been enabled by the rapidly
evolving technique with the multi-channel phased array sur-
face coils and parallel imaging acquisition [14,15]. Whole-body
MR imaging with fast spin-echo (SE) short invarsion time
invarsion recovery (STIR) sequences has been shown to be
valuable for the evaluation of metastatic bone disease, staging
and assessment of multifocal disease in adults [16–19], and for
staging newly diagnosed small cell tumors in children [20]. MR
has a complementary role to blind bone marrow biopsy in
evaluating marrow involvement in both NHL and HD [21].
Neoplastic tissues as lymphomatous tissue have increased
water that has high signal on STIR imaging enabling the detec-
tion of diseases [22,23].
The goal of this study is to evaluate the role of whole-body
MRI in diagnosis and staging of lymphoma.2. Material and methods
2.1. Patients
Our study included 21 newly diagnosed histologically proven
lymphoma patients (12 males and 9 females) with age range
of 12–70 years (mean 42 years). All patients were included
after they had been properly informed and provided written in-
formed consent. Exclusion criteria were contraindication to
CT and MR imaging (e.g., pregnancy, and pacemaker, metallic
implant, severe claustrophobia). All patients were subjected to
physical examination, complete blood count, renal and hepatic
function tests, conventional staging procedures (bone marrow
biopsy and CT scans) and whole body MRI, radiologicalexaminations were performed within one week of each other,
before the start of treatment, and after 3 months of follow up.
2.2. Conventional staging procedures
2.2.1. CT scanning
CT imaging was performed using helical scanner (HiSpeed,
GE Medical Systems). It included contrast enhanced imaging
of the head, neck, chest, abdomen and pelvis. Examination
of the head and neck was done with the acquisition of contig-
uous sections of 5-mm thickness while examination of the
chest, abdomen and pelvis was done using 10 mm collimation.
All patients received oral (Telebrix Gastro) and intravenous
non-ionic contrast medium before scanning. The administered
amount of CT contrast agents was adjusted according to age
and weight (2 ml/kg).2.2.2. Bone marrow assessment (bone marrow biopsy)
Marrow aspirates were taken from both iliac crests stained
with Giemsa stain. Trephine biopsy samples were decalciﬁed
and stained with hematoxylin and eosin.2.3. Whole-body MR imaging
Each patient included for study underwent imaging on a 1.5-
T MR (Achieva, Philips Medical Systems, Netherland B.V.)
scanner using a moving tabletop and tabletop extender, gen-
erating a longitudinal ﬁeld of view of 200 cm and transverse
ﬁeld of view of 53 cm. In each case, images were acquired
with a body coil with a moving tabletop technique in coronal
and axial planes. The patients were supine with the arms
placed by their sides and placed feet-ﬁrst in the imager.
The rolling table platform was positioned so that a transverse
section in the isocenter of the imager aligned the basal thorax
directly cranial to the liver. After obtaining localizing se-
quences, the entire body was covered from the vertex to the
heels by coronal FSE STIR whole body sequences. Coronal
scans were acquired in seven contiguous stations with 25 con-
secutive slices at each station. Scanning was done with a slice
thickness of 7 mm and an interslice of 1 mm. Images were ac-
quired under free breathing, except for the stations covering
the chest, abdomen, and pelvis, which were acquired using
breathholding. Images acquired in matching positions were
automatically aligned to generate a seamless whole-body
coronal image using software implemented in the standard
operating console. Tissue excitation used FSE STIR with a
TR of 6600 ms, a TE of 70 ms scan time of 39.4 s per station,
seven stations in total. Axial images were acquired using a
similar moving tabletop technique and STIR tissue excitation.
After FSE STIR whole body MR image acquisition in the
coronal and axial planes T1-weighted tissue excitation (TR/
TE, 214/5) in coronal and axial planes were acquired using
the same techniques.
Table 2 Detection of nodal and extra-nodal lymphoma
lesions by FSE STIR whole body MRI and conventional
staging procedures.
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Both conventional staging procedures (including computed
tomography and bone marrow biopsy) and FSE STIR whole
body MR imaging data ﬁndings were used in the staging of
lymphoma patients using Modiﬁed Ann Arbor staging system
(Table 1). To facilitate staging by either method the patient
was evaluated for nodal and extra-nodal involvement. Con-
cerning nodal analysis the body was divided into lymph node
or disease stations (intraparotid, Waldeyer ring, retropharyn-
geal, submandibular, cervical, supraclavicular, axillary, inter-
nal mammary, cardiophrenic, anterior mediastinum, right
and left paratracheal including aortopulmonary nodes, subcar-
inal, hilar, posterior mediastinum, retrocrural, porta hepatis,
upper retroperitoneal (celiac and peripancreatic nodes), lower
retroperitoneal, mesenteric, iliac and inguinal). Lymph nodes
greater than 10 mm in the short-axis diameter were considered
positive at CT and MR sequences. Extranodal involvement
was divided into parenchymal, serosal and bone marrow
involvement where pathology was evaluated by both methods
(conventional staging procedures and coronal FSE STIR
whole body MRI) as follows: area of abnormal attenuation/
signal intensity (relative to the surrounding tissue) or mass le-
sion in the liver, spleen, kidney, stomach, bowel, pancreas,
nodule or inﬁltration in the lung. Serosal involvement was
evaluated as effusions in serosal cavities. Bone marrow
involvement was diagnosed as foci of abnormal high signal
in bone marrow on MR imaging, sclerotic or lytic bone lesions
on CT and positive bone marrow biopsy for the presence of
lymphoma.
The number of involved sites in lymph node stations,
parenchymal organs serosal cavities and bone marrow, de-
tected on coronal FSE STIR whole body MR marrow imaging
and on conventional staging procedures were compared. The
proof of diagnosis or a ﬁnal diagnosis was based on all imag-
ing performed and on the outcome at follow up. Differences in
staging between coronal FSE STIR whole-body MRI and con-
ventional staging procedures were resolved using follow up
studies (including CT & MRI) as the standard of reference.
At follow-up, enlarged nodes, parenchymal organs, serosal
and bone marrow abnormalities that decreased in size at fol-
low-up imaging were considered positive for the presence of
malignant lymphoma.
Agreement and disagreement between whole-body MRI
and conventional procedures regarding lesions detection and
staging according to the Ann Arbor staging system were calcu-
lated, along with binomial exact 95% conﬁdence intervalsTable 1 Cotswold modiﬁcation of Ann ArboR Staging of
Hodgkin and non-Hodgkin lymphoma [24].
Stagea Criteria
I In 1 lymph region only
II InP 2 lymph regions on the same side of the diaphragm
III In the lymph nodes, spleen, or both and on both sides
of the diaphragm
IV Extranodal involvement (e.g., bone marrow, lung, liver)
a Subclassiﬁcation E indicates extranodal involvement adjacent to
an involved lymph node (e.g., disease of mediastinal nodes and hilar
adenopathy with adjacent lung inﬁltration is classiﬁed as stage IIE).(CIs), using SPSS version 10 software. An unweighted k anal-
ysis (Kappa test) was used to test agreement between whole
body MR imaging, conventional procedures and ﬁnal diagno-
sis for lesion detection and staging. A k less than 0.2 was con-
sidered to indicate poor agreement; 0.21–0.40, fair agreement;
0.41–0.60, moderate agreement; 0.61–0.80, good agreement;
and 0.81–1, very good agreement. P value < 0.05 was consid-
ered signiﬁcant.
3. Results
A total of 21 newly diagnosed histologically proven lymphoma
patients (16 patients had NHL and 5 patients had HD) under-
went initial staging by two separate procedures; conventional
staging procedures (included computed tomography and bone
marrow biopsy) and coronal FSE STIR whole body MRI.
Twenty one patients had a total of 145 abnormalities accord-
ing to the ﬁnal diagnosis proved by all the imaging performed
and on the outcome at follow up (Table 2). One hundred and
twenty four were correctly diagnosed by conventional staging
procedures. Whole body MRI correctly diagnosed 144 abnor-
malities with 1 false negative abnormality, and had 3 false po-
sitive abnormalities with a total of detected abnormalities by
coronal FSE STIR whole body MRI 147 abnormality. A total
of 94 lymph nodes for malignant lymphoma were present, 89
positive nodes were detected by conventional staging proce-
dures, however, coronal FSE STIR whole body MRI detected
93 diseased nodes with 1 false negative and 3 false positive
nodes with a total of 96 positive nodes as shown in Table 2.
Fifty-one lesions were present as extranodal lymphomatous
involvement (17 parenchymal, 2 serosal, 32 bone marrow);
conventional staging procedures detected 35 out of the 51 le-
sions and whole body MRI correctly detected all the 51 lesions.
Parenchymal lymphomatous involvement were present in 17
organs and were as follows: liver (n= 5), spleen (n= 6), the
kidneys (n= 1), stomach (1), bowel (1) and lungs (n= 3).
On conventional staging procedures, 15 of the 17 involved
parenchymal organs were correctly diagnosed, and on whole-
body MR imaging, all organ involvements were detected.
Two pleural effusions were present and were correctly diag-
nosed by both procedures.FSE STIR whole
body imaging
Conventional
staging
procedures
Final
diagnosis
Nodal lesions 96 89 94
Extra-nodal lesions 51 35 51
*Parenchymal 17 15 17
Liver 5 4 5
Spleen 6 6 6
Kidneys 1 0 1
Stomach 1 1 1
Bowel 1 1 1
Lung 3 3 3
*Serosal (pleural) 2 2 2
*Bone marrow Foci 32 18 32
Total 147 124 145
80 M.A. El-Hariri et al.Twenty one patients had 32 bone marrow lesions according
to the ﬁnal diagnosis. Coronal FSE STIR whole-body MR
imaging detected more bone marrow lesions (n= 32) than
did conventional staging procedures (n= 18). Conventional
staging procedures detected only 18 of 32 involved sites.
So, whole body MRI correctly diagnosed (144) lesions out
of (145) lesions (99.3%; 95% CI: 95.6–100.0%). On the other
hand conventional staging correctly diagnosed (124) lesions
out of (145) lesions (85.5%; 95% CI: 78.5–90.6%). Both whole
body MRI and conventional procedures were in agreement in
(125) lesions (124 positive and one negative lesions), while
there was no agreement in [23] lesions with overall agreement
of Kappa test 0.07 (P< 0.05).
The ﬁnal clinical staging of the 21 patients as shown in illus-
trative cases (Figs. 1–4) was as follows; stage I (n = 3), stage II
(n = 4), stage III (n = 6) and stage IV (n = 8). Coronal FSEFigure 1 Male patient, 65 years old initially staged as stage IE lymph
show multiple small anterior (a) and posterior (b) pulmonary nodule
pleural effusion as well as single enlarged mediastinal lymph node s
enhanced computed tomography (d–f) show the anterior (d) and the p
station and the mild right sided pleural effusion (f).STIR whole body MRI correctly staged 20 out of 21 patients
referring to the ﬁnal staging Kappa test 0.93 (P< 0.001) as
shown in Tables 3 and 4, however, 1 patient only in stage II
was overstaged as in stage III. This patient had multiple en-
larged abdominal lymph node stations with additional 2 false
positive mediastinal lymph node stations. Concerning clinical
staging by conventional procedures 17 patients were correctly
staged, Kappa test 0.74 (P< 0.001). All patients with stage I
were correctly staged (3 of 3). In stage II: 3 out of 4 patients
were correctly staged and 1 patient was understaged as stage
I due to an additional right cervical lymph node that was
not detected by CT and detected by MRI. In stage III: all
the 6 patients were correctly staged. In stage IV: 5 out of 8 pa-
tients were correctly staged and 3 patients were understaged (2
cases as stage III and one case as stage II) as in these 3 patients
coronal FSE STIR whole body MRI revealed multifocal boneoma. Selected images of coronal FSE STIR whole body MRI (a–c)
s displaying high signal intensity associated with mild right sided
tation (c) displaying slightly high signal intensity. Axial contrast
osterior (e) pulmonary nodules, the single mediastinal lymph node
Figure 2 Female patient, 45 years old, clinically staged as stage III lymphoma. Selected images of coronal FSE STIR whole body MRI
(a–c) show multiple enlarged variable sized amalgamated lymph node stations on both sides of the diaphragm at the mediastinal (a) and
abdominal (b and c) regions displaying high signal intensity. Axial STIR (d–f) show the different abdominal lymph node stations which is
of high signal intensity. Axial CT cuts (g–i) show the enlarged mediastinal (g) and abdominal (h and i) lymph node stations.
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and blind iliac bone marrow biopsy.
4. Discussion
Assessment of pathological classiﬁcation and disease extent in
malignant lymphoma is crucial for the prognosis and therapy.
Accurate staging is important in treatment planning and
selection and monitoring the appropriate therapy [25–31,2].
Contrast enhanced computed tomography is the imagingtechnique commonly used due to its widespread availability
and relatively low cost, however, the major disadvantages of
it is exposure of the patient to ionizing radiation which may in-
duce secondary cancers and the administration of iodinated
contrast agents which may cause adverse reactions as nephro-
toxicity and anaphylactic shock [26–28,32]. Whole body MRI
offers a whole body overview of disease that inﬁltrates
throughout the body, such as carcinoma and lymphoma. It
does not involve any radiation exposure or administration of
oral or intravenous contrast media. FSE STIR whole body
Figure 3 Female patient, 44 years old initially staged as stage V lymphoma. Selected images of coronal FSE STIR whole body MRI (a–
e) show heterogeneous high bone marrow signal intensity lesions involving both femoral (a and b)and tibial shafts (c and d) which were
not detected by computed tomography or bone marrow biopsy.
82 M.A. El-Hariri et al.MRI offers fat suppression over the whole body without the
need of accurate shimming and so is useful for whole bodyMRI. Lymphomatous tissue, like all neoplastic tissues, has
increased water content that returns high signal on STIR
Figure 4 Female patient, 19 years old initially staged as stage V lymphoma due to diffuse bone marrow involvement. Selected images of
coronal FSE STIR whole body MRI (a–c) show high bone marrow signal intensity lesion involving the left humeral head and upper shaft,
another focal high signal intensity lesions are seen at right femoral mid-shaft (b) and left femoral upper shaft (c). These lesions were not
detected by computed tomography or bone marrow biopsy.
Table 3 Initial lymphoma staging by FSE STIR whole body MRI and conventional staging procedures.
Stage Correct FSE STIR whole
body MRI staging No.
Incorrect FSE STIR whole
body MRI staging No.
Correct conventional
staging No.
Incorrect conventional
staging
Final
staging No.
I 3 0 3 0 3
II 3 1 (Overstaged
as stage III)
3 1 (Understaged
as stage I)
4
III 6 0 6 0 6
IV 8 0 5 3 (2 Understaged
as stage III and 1 understaged
as stage II)
8
Total 20 1 17 4 21
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of bone marrow, lymph nodes and parenchymal organs [33–
36,13,22,23].
FSE STIR whole body MRI was signiﬁcantly more accu-
rate than conventional staging procedures including CT and
bone marrow biopsy in detecting nodal and extra-nodal lym-
phometous lesions [(99.3%; 95% CI: 95.6–100.0%) versus
(85.5%; 95% CI: 78.5–90.6%)]. This is consistent with other
study [37] who reported that whole-body MR imaging was sig-
niﬁcantly more sensitive in detecting sites of lymphomatous
involvement than was the conventional imaging (sensitivity
was 99% vs. 84%, P< 0.001).This study included 21 patients had 94 positive nodal sta-
tions for lymphoma. CT detected 89 nodal stations of them,
however, FSE STIR whole body MRI detected 93 one plus an-
other 3 false positive nodal stations. The explanation of higher
accuracy of FSE STIR whole body MRI in detecting nodal le-
sions is its high spatial resolution and superior soft tissue con-
trast. This is consistent with the previous study [4] which
proved high sensitivity for the detection of lymph nodes larger
than 12 mm and the only missed nodes were calciﬁed. In this
study we had 3 false positive nodal station detected by FSE
STIR whole body MRI when compared with T1WI at which
lymph nodes appear of low signal intensity against the high
Table 4 Kappa test and probability factor of both FSE STIR
whole body MRI and conventional staging.
FSE STIR whole
body MR staging
Conventional staging
Kappa test 0.93 0.74
P value <0.001 <0.001
84 M.A. El-Hariri et al.signal intensity of the surrounding fat. This is also found in
other study [4] in which whole body MRI detected only 1 false
positive nodal station concerning lymph nodes above 12 mm
and the study [37] in which FSE STIR whole body MRI de-
tected all the positive 51 nodal stations plus additional 6 false
positive nodal stations which revealed either diffuse edematous
changes or ascites as the cause of the increased signal. The 1
false negative or missed lymph node station by FSE STIR
whole body MRI in our study was mediastinal but did not af-
fect the staging as there were other several detected positive
mediastinal stations in the same patient.
Both CT and FSE STIR whole body MRI were equal and
diagnosed all parenchymal and seosal lesions, however, in the
other study [37] there were 14 parenchymal lesions, 13 lesions
detected by conventional methods and 15 lesions detected by
whole body MRI (1 false positive lung lesion) but both proce-
dures detected 4 out of 5 serosal lesions.
FSE STIR whole body MRI was more accurate in detecting
bone marrow involvement by lymphoma than combined CT
and bone marrow biopsy. FSE STIR whole body MRI de-
tected all bone marrow lesions (n= 32), however, conven-
tional methods detected only 18 lesions. This is consistent
with other previous studies [38,37] in which conventional
methods detected 7 out of 18 bone marrow lesions, however,
FSE STIR whole body MRI detected all the 18 bone marrow
lesions plus 1 false positive lesion due to recent biopsy.
The limited sensitivity of the blind bone marrow biopsy in
the detection of bone marrow lesions in malignant lymphoma
can be explained by the sampling errors as MRI pattern of
bone marrow inﬁltration is nodular in 65% of patients with
Hodgkin’s lymphoma and in 85% of aggressive lymphomas.
This is why iliac crest biopsy may be normal despite bone mar-
row inﬁltration in other areas. Whole-body MRI-guided bone
marrow biopsy has the potential to reduce sampling errors. In
addition, this approach may reduce the number of unnecessary
bone marrow biopsies, which are invasive, painful, and have a
small but non-negligible risk of complications [39–41].
Concerning clinical staging of our patients FSE STIR
whole body MRI correctly staged 20 out of 21 patients but
incorrectly staged 1 patient of stage II as stage III due to addi-
tional false positive lymph nodes detected by FSE STIR whole
body MRI. Conventional staging procedures correctly staged
17 and incorrectly staged 4 cases. One of these 4 cases was
stage II and understaged as stage I due to missed right cervical
lymph node not detected by CT, however, the other 3 cases
were stage IV and understaged due to missed bone marrow le-
sions by CT and bone marrow biopsy. This study is consistent
with two previous studies that reported the feasibility of
whole-body MRI using STIR. The ﬁrst one [4] performed a
study in 23 adults (both for initial staging and restaging) and
found that whole-body MRI using STIR enables disease stag-
ing and that it compared favorably with CT for the detectionof lymph nodes larger than 12 mm in short-axis diameter and
for the detection of bone marrow involvement. The other one
[37] performed a study in 8 children (both for initial staging
and restaging) and reported that whole-body MRI using STIR
is a sensitive technique for staging malignant lymphoma and
that it is superior to blind bone marrow biopsy and conven-
tional imaging in the detection of bone marrow involvement,
at initial diagnosis. When bone marrow involvement is de-
tected by FSE STIR whole body MRI and missed by other
conventional modalities it overstages the patient to stage IV
whatever its stage by conventional methods so if the MR study
was performed as ﬁrst imaging study and showed bone mar-
row involvement consistent with a stage IV, further imaging
might not be necessary.
FSE STIR whole body MRI is a highly sensitive method in
initial staging of lymphoma as it offers a whole view of the
body including positive lymph node stations, parenchymal,
serosal and bone marrow lesions. FSE STIR whole body
MRI is more accurate than conventional staging procedures
in staging of lymphoma especially in the detection of bone
marrow involvement.
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